Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)
Rhea-AI Summary
Outlook Therapeutics (NASDAQ:OTLK), a biopharmaceutical company specializing in bevacizumab treatments for retina diseases, will present at the EURETINA Innovation Spotlight during the 25th EURETINA Congress. The presentation titled "Optimising the treatment of retinal disease" will be delivered by CEO Bob Jahr on September 3, 2025 at 16:10 PM CEST / 10:10 AM EDT in Paris, France.
Positive
- None.
Negative
- None.
News Market Reaction 14 Alerts
On the day this news was published, OTLK gained 2.29%, reflecting a moderate positive market reaction. Argus tracked a trough of -10.0% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $865K to the company's valuation, bringing the market cap to $39M at that time.
Data tracked by StockTitan Argus on the day of publication.
ISELIN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will present at the EURETINA Innovation Spotlight being held as part of the 25th EURETINA Congress on September 3, 2025 in Le Palais des Congrès, Paris.
Details for the presentations are as follows:
Session: VEGF Related and Other Retinal Indications
Title: Optimising the treatment of retinal disease
Presenter: Bob Jahr, Chief Executive Officer of Outlook Therapeutics
Date and Time: Wednesday, September 3, 2025, 16:10 PM CEST / 10:10 AM EDT
For more information about this event, please visit EIS 2025.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) to optimize the standard of care for bevacizumab for the treatment of retina diseases. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK as a treatment for wet AMD.
In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.
Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
OTLK@jtcir.com
FAQ
When is Outlook Therapeutics (OTLK) presenting at EURETINA 2025?
Who will be presenting for Outlook Therapeutics (OTLK) at EURETINA 2025?
What is the topic of Outlook Therapeutics' (OTLK) EURETINA 2025 presentation?
Where is the EURETINA 2025 conference being held?
